m-PEG8-Tos, with  CAS 82217-01-4, is a highly functionalized discrete monodisperse polyethylene glycol (PEG) derivative that has become a critical building block in modern organic synthesis, bioconjugation, and biopharmaceutical development. The name of the compound breaks down to reflect its core structure: the “m” indicates a terminal monomethyl ether group that blocks unwanted cross-linking reactions, “PEG8” denotes eight consecutive ethylene glycol repeating units, and “Tos” refers to the terminal p-toluenesulfonate (tosylate) functional group. Unlike polydisperse PEG mixtures that contain a range of molecular weights, m-PEG8-Tos has a fixed, exact molecular structure, making it ideal for applications that require high reproducibility and precise chemical characterization. Over the past two decades, as demand for well-defined biopharmaceutical intermediates has grown, this compound has emerged as a go-to reagent for researchers and manufacturers working on targeted drug delivery, peptide modification, and diagnostic development.

Chemically, m-PEG8-Tos has a molecular formula of C26H46O11S and a molar mass of approximately 566.7 grams per mole. At room temperature, it typically exists as a colorless to pale yellow low-viscosity liquid or low-melting solid, depending on storage conditions. One of its most valuable chemical properties is the reactivity of the tosylate group: tosylate is an excellent leaving group for nucleophilic substitution reactions, allowing m-PEG8-Tos to readily react with a wide range of nucleophiles including primary amines, thiols, carboxylates, and alkoxides under mild reaction conditions. This reactivity makes it easy to graft the eight-unit ethylene glycol chain onto other molecules of interest for research or manufacturing. The compound also has favorable solubility properties: it is fully soluble in most common organic solvents including dichloromethane, chloroform, methanol, and tetrahydrofuran, while the eight hydrophilic ethylene glycol units also give it good solubility in aqueous buffer systems. This dual solubility allows researchers to use m-PEG8-Tos in both organic-phase and aqueous-phase reaction setups, expanding its range of potential applications. Another key advantage of its discrete structure is that it eliminates batch-to-batch variability in molecular weight, a common issue with polydisperse PEG products that can complicate regulatory approval for clinical-stage drugs.

The most common use of m-PEG8-Tos (CAS 82217-01-4) is as a precursor for PEGylation, the process of covalently attaching polyethylene glycol chains to therapeutic molecules. PEGylation is a well-established technique to improve the pharmacokinetic properties of small molecule drugs, peptides, proteins, and antibodies: it increases water solubility of hydrophobic payloads, extends circulation half-life by reducing renal clearance and proteolytic degradation, and lowers immunogenicity by shielding the therapeutic molecule from the host immune system. Because m-PEG8-Tos is monodisperse, it produces PEGylated products with a consistent molecular weight and structure, which is a requirement for regulatory approval from agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). In the fast-growing field of antibody-drug conjugates (ADCs), m-PEG8-Tos is widely used as a building block for hydrophilic linkers that connect cytotoxic payloads to monoclonal antibodies. The 8-unit ethylene glycol spacer improves the overall stability of the ADC in circulation, reduces off-target toxicity, and preserves the binding affinity of the antibody for its target. It is also commonly used to synthesize other functionalized PEG derivatives for click chemistry: by substituting the tosylate group with azide, alkyne, maleimide, or amine functional groups, researchers can produce a range of heterobifunctional PEG reagents that are used for site-specific bioconjugation. More recently, m-PEG8-Tos has found use in the production of PEGylated lipid nanoparticles (LNPs) for mRNA vaccine and gene therapy delivery. The discrete PEG chain added to the surface of LNPs prevents particle aggregation, reduces immune clearance, and improves the overall biodistribution of the nanoparticle, with the monodisperse structure enabling more consistent LNP performance across production batches.

Proper handling, storage, and quality control are important to preserve the reactivity and performance of m-PEG8-Tos. While the compound is not classified as an acutely hazardous material, standard laboratory safety protocols should always be followed: users should wear nitrile gloves, safety goggles, and a lab coat when handling the compound, and avoid direct contact with skin or eyes, as it can cause mild irritation in sensitive individuals. For long-term storage, m-PEG8-Tos should be kept in a tightly sealed container at 2 to 8 degrees Celsius, away from direct sunlight, heat sources, and moisture. Prolonged exposure to high temperatures or high humidity can lead to hydrolysis of the tosylate group, which reduces the compound’s reactivity and can introduce unwanted impurities into subsequent reactions. For applications in biopharmaceutical manufacturing and clinical research, high purity is non-negotiable. Reputable suppliers typically offer m-PEG8-Tos with purity of 95% or higher, verified by high-performance liquid chromatography (HPLC), nuclear magnetic resonance (NMR) spectroscopy, and mass spectrometry. Common impurities include unreacted monomethyl PEG8 and di-tosylated PEG8 byproducts, both of which can cause unwanted side reactions like cross-linking in bioconjugation that ruin experimental results or manufacturing batches. GMP-grade m-PEG8-Tos is also available for clinical and commercial manufacturing, with full documentation to meet regulatory requirements.

Looking forward, the demand for m-PEG8-Tos (CAS 82217-01-4) is expected to continue growing as the biopharmaceutical industry expands its focus on well-defined, reproducible therapeutic products. Traditional polydisperse PEGs are increasingly being replaced by discrete monodisperse oligoethylene glycol derivatives in clinical development, as they offer more consistent chemical properties and easier regulatory characterization. Ongoing research is exploring new applications for m-PEG8-Tos in areas like prodrug development, where the 8-unit PEG chain provides an optimal balance of hydrophilicity and size to enhance tumor targeting via the enhanced permeability and retention (EPR) effect. In the field of diagnostic biosensors, m-PEG8-Tos is used to functionalize sensor surfaces, adding a hydrophilic PEG layer that reduces non-specific protein binding and improves the sensitivity and accuracy of point-of-care diagnostic tests. While it is a specialized chemical intermediate, m-PEG8-Tos’s unique combination of controlled structure, ideal reactivity, and dual solubility makes it an indispensable tool for modern chemical and biological research, underpinning many of the recent advances in targeted therapy and nucleic acid delivery.